Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Ferreras-Antolin has a total of 191 co-authors. Here are the top co-authors by number of shared publications:

  • Adilia Warris

    MRC Centre for Medical Mycology, University of Exeter , Exeter , UK

    5 shared publications
  • Adilia Warris

    Pediatric Infectious Diseases and Immunology, Great Ormond Street Hospital for Children, London WC1N 3JH, UK

    5 shared publications
  • David Moreno-Pérez

    From the Paediatric Infectious Diseases Unit, and Paediatric Respiratory Unit, Department of Paediatrics, Malaga Regional University Hospital, Málaga, Spain

    2 shared publications
  • Elena María Rincón-López

    Hospital General Universitario Gregorio Marañón

    2 shared publications
  • Elisavet Chorafa

    Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital , Thessaloniki, 54642

    2 shared publications
  • Francisco Javier Pérez-Frías

    From the Paediatric Infectious Diseases Unit, and Paediatric Respiratory Unit, Department of Paediatrics, Malaga Regional University Hospital, Málaga, Spain

    2 shared publications

Latest Publications

  • Open Access

    Lateral-Flow Device (LFD) Aspergillus Antigen Detection in Broncho-Alveolar Lavage (BAL) Fluid in Paediatrics: A Literature Review and Pilot Study

    by Zeynep Ergenc, Kit McDowell, Andres Almario, Adilia Warris, Laura Ferreras-Antolin

    Background: Invasive aspergillosis (IA) causes significant morbidity and mortality in immunocompromised children, yet diagnosis remains challenging due to non-specific clinical and radiological findings and the need for invasive procedures. Aspergillus lateral flow devices (Asp-LFD) offer rapid point-of-care testing, particularly for bronchoalveolar lavage (BAL), but paediatric data is limited. Methods: In this study, we combined a literature review and a prospective pilot study to evaluate the use of Asp-LFD in paediatrics. We performed a prospective single-centre study evaluating BAL Asp-LFD in immunocompromised children with suspicion of pulmonary IA. Clinical, radiological, and microbiological data were collected and BAL samples were analysed using the Asp-LFD as well as standard investigations. Results: Paediatric literature review retrieved only one study evaluating serum Asp-LFD which reported low sensitivity (12.1%) but perfect specificity (100%). In contrast, 14 adult studies evaluating Asp-LFD were identified. BAL Asp-LFD sensitivity was reported in 10 studies (71.4%), with a median of 73.0% (min-max: 38–100%), while specificity was reported in nine studies (64.3%) ranged from with a median of 86.0% (min-max: 76–100%). Twenty children were included. Nineteen (95%) received mould-active antifungal therapy before BAL (median: 9 days, IQR 6–16). BAL Asp-LFD was positive in 2/20 patients (10%), without any other evidence of probable or proven IA; conversely, it was negative in one patient classified as having probable IA. BAL culture was negative for moulds in all cases. Conclusions: To our knowledge, this is the first study evaluating BAL Asp-LFD in children. Despite encouraging performance in adults, BAL Asp-LFD demonstrated low positivity in a highly antifungal-pretreated paediatric cohort with delayed sampling. Further paediatric studies with earlier sampling are required to define the role of lateral flow tests.

  • Antifungal Prescribing in European Pediatric Intensive Care Units: Results of a Multinational 3-Month Weekly Point-Prevalence Survey

    by Elisavet Chorafa, Elias Iosifidis, Aisha Abdalla Alkhaaldi, Ana Arias, Benhur Sirvan Cetin, Maia De Luca, Marieke Emonts, Laura Ferreras-Antolin, Elisabetta Ghimenton-Walters, Carlos D Grasa, et al.

    Background: Critically ill pediatric patients admitted to the pediatric intensive care unit (PICU) are highly vulnerable to infections, including invasive fungal diseases and antifungal agents are frequently prescribed. Little is known about antifungal usage in PICUs across Europe. Methods: A multinational 3-month weekly point-prevalence study for measuring antifungal drug use was organized. Eigtheen PICUs (16 hospitals) in 10 countries in the European region participated. All patients hospitalized in the participating PICUs and receiving systemic antifungals were included. Information about ward demographics was collected once; weekly ward and patient data were collected prospectively for the 12-week study period and entered in REDCap database. Results: Among 18 PICUs, 8 (44%) followed prophylactic practices for targeted group of patients, 7/18 (39%) had an antifungal stewardship program and the majority (16/18, 89%) had the capacity of biomarker utilization (16/16 galactomannan, 13/16 beta-D-glucan, and 9/16 pan-fungal PCR). One hundred one courses in equal number of patients were recorded; 14 for patients aged <3 month, 87 for patients ≥3 month. Malignancy was the most common underlying condition among patients aged ≥3 month (29%) followed by surgery/trauma (25%), whereas all patients <3 month had undergone a recent surgery. Indication for antifungal prescribing was prophylaxis in 38% and treatment in 62% [empirical (57%), preemptive (13%), and targeted (30%)]. Fluconazole was the most common agent both for prophylaxis and treatment, whereas liposomal amphotericin B was the most frequent agent for targeted treatment. The majority (63%) of patients on prophylaxis were oncology or transplant patients. Common reasons for empirical and targeted treatment were persistent fever/other signs of infections in high-risk patients (61%) and Candida infections (100%), respectively. For targeted treatment, the most frequent pathogens were Candida albicans (37%) and Candida parapsilosis (32%). Conclusions: Most antifungal prescriptions across European PICUs were for treatment. Fluconazole was the most frequently prescribed antifungal. These surveillance data can guide antifungal stewardship strategies in PICUs.


  • Open Access

    The burden of Neonatal Invasive Candidiasis in Low- and Middle-Income Countries: a systematic review and meta-analysis

    by Daniel Hsiang-Te Tsai, Ian Chang-Yen Wu, Ling-Fang Chang, Marie Jen-Huey Lu, Brishti Debnath, Nelesh P Govender, Mike Sharland, Adilia Warris, Yingfen Hsia, Laura Ferreras-Antolin

    Background Invasive Candida infection remains a significant threat to neonates worldwide. Most evidence on neonatal invasive candidiasis (NIC) comes from high-income countries (HICs), leaving the burden and characteristics of NIC in low-and middle-income countries (LMICs) poorly described. This study aimed to investigate the incidence, case-fatality rates (CFR), epidemiology and aetiology of NIC in LMICs. Methods We conducted a systematic literature review and meta-analyses of all eligible studies in 17 databases published from inception until April 2022 focussing on microbiologically-confirmed NIC in LMICs. Findings A total of 257 articles were included, with 10,994 NIC cases from 27 LMICs. The overall incidence rate was 2.6% (95% CI: 2.2%-3.0%). Regional disparities were evident, with South-East Asia reporting the highest incidence rate (6.3%; 95% CI: 3.2%-10.3%). The mean gestational age and birth weight were 31.4 weeks (standard deviation [SD] 3.3) and 1,530 g (SD 644.6) respectively. Among 10,087 included isolates, the predominant species was C. albicans (39.0%), followed by C. parapsilosis (24.8%) with marked differences in species distribution across World Health Organization regions. Fluconazole was the most commonly-used agent for NIC treatment (55.4%; 1,567/2,826). Overall, 24.8% (1,128/6,613) of isolates with available data were resistant to fluconazole. The pooled estimated CFR was 18.7% (95% CI: 15.5%-22.1%). Conclusions A higher NIC incidence rate and CFR in LMICs is noted compared to HICs, although infected babies were less premature with a higher birth weight. The proportion of fluconazole-resistant isolates was high. Prevention and treatment strategies for NIC need to be targeted to LMIC settings.


  • Open Access

    Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

    by Emma V Thorley, Jennifer Hatch, Monica Li, Sharlene N Mashida, Elio Castagnola, Alessio Mesini, Thomas Lehrnbecher, Andreas H Groll, Adilia Warris, Laura Ferreras-Antolin

    Background: Liposomal amphotericin B (LAmB) is widely used for prophylaxis in paediatric patients at high risk of invasive fungal diseases (IFD) but its use is off-label and there is significant variability in dosage and frequency. This systematic review was conducted to evaluate the published data on prophylactic LAmB use in the paediatric population and to present the reported proportions of breakthrough IFD and the associated toxicity profile. Methods: EMBASE, Medline, Web of Science and the Cochrane Database were systematically searched for primary research reporting on the use of LAmB as prophylaxis for IFD in the paediatric population up to 7 December 2023, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: Twenty studies, comprising three clinical trials, 12 cohort studies, two point-prevalence surveys and three pharmacokinetic (PK) studies, with 2015 patients were included. A total of 717 cases presented individual patient data. Breakthrough IFD occurred in 7.2% (49/676). The most recognized side effects were hypokalaemia in 23.2% (125/538) and derangement of liver function tests in 15.0% (49/327). Discontinuation due to toxicity occurred in 6.0% (30/503) of patients. Of the four studies reporting PK data, two examined serum levels of LAmB, one analysed CSF levels and the remaining study peritoneal levels. Conclusions: Despite widespread use of prophylactic LAmB, this systematic review highlights the paucity of paediatric data supporting its use. The heterogeneity observed in populations, dosing regimens and study design prevents conclusions being reached on its efficacy or the superiority of one dosing regimen. Overall, there is a clear need for further high-quality robust clinical data and targeted PK studies.


  • Open Access

    Neosartorya udagawae pulmonary infection requiring a surgical treatment in a paediatric haematopoietic progenitor cell recipient

    by Olga S. Tatarinova, Caroline L. Furness, Andrew M. Borman, Joy Barber, Nagarajan Muthialu, Laura Ferreras-Antolin


  • Open Access

    Novel antivirals for severe enterovirus infection in immunocompromised hosts; A case series

    by Andrea Meinhardt, Liam Reilly, Marios Kaliakatsos, Khaled Abdel-Aziz, Sondus Alsharidah, Istvan Bodi, Claire Booth, Kritika Chetty, Jennifer Evans, Laura Ferreras-Antolín, et al.


  • Open Access

    Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS study

    by Aislinn Cook, Laura Ferreras-Antolin, Bethou Adhisivam, Daynia Ballot, James A Berkley, Paola Bernaschi, Cristina G Carvalheiro, Napaporn Chaikittisuk, Yunsheng Chen, Vindana Chibabhai, et al.

    Neonatal invasive candidiasis (NIC) has significant morbidity and mortality. Reports have shown a different profile of those neonates affected with NIC and of fluconazole resistant Candida spp. isolates in low-and-middle-income -countries (LMICs) compared to high-income-countries (HIC). We describe the epidemiology, Candida spp. distribution, treatment and outcomes of neonates with NIC from LMICs enrolled in a global, prospective, longitudinal, observational cohort study (NeoOBS) of hospitalised infants < 60 days postnatal age with sepsis (August 2018-February 2021). 127 neonates from 14 hospitals in 8 countries with Candida spp. isolated from blood culture were included. Median gestational age of affected neonates was 30 weeks (IQR: 28-34) and median birth weight was 1270 g (IQR: 990–1692). Only a minority had high risk criteria, such as being born < 28 weeks, 19% (24/127), or birth weight < 1000 g, 27% (34/127). The most common Candida species were C. albicans (n = 45, 35%), C. parapsilosis (n = 38, 30%) and Candida auris (n = 18, 14%). The majority of C. albicans isolates were fluconazole susceptible, whereas 59% of C. parapsilosis isolates were fluconazole resistant. Amphotericin B was the most common antifungal used [74% (78/105)], followed by fluconazole [22% (23/105)]. Death by day 28 post-enrolment was 22% (28/127). To our knowledge, this is the largest multi-country cohort of NIC in LMICs. Most of the neonates would not have been considered at high risk for NIC in HICs. A substantial proportion of isolates was resistant to first choice fluconazole. Understanding the burden of NIC in LMIC is essential to guide future research and treatment guidelines. Our study describes neonates from LMIC with neonatal invasive candidiasis (NIC). Most of them were outside the groups considered at high risk for NIC described in HIC. Candida spp. epidemiology was also different. The mortality was high (22%). Further research in these settings is required.


  • Nystatin is commonly prescribed as prophylaxis in children beyond the neonatal age

    by Harshani Jayawardena-Thabrew, Adilia Warris, The PASOAP Group, Laura Ferreras-Antolin

    The indications for nystatin as prophylaxis or treatment are limited. In the PASOAP (Pediatric Antifungal Stewardship Optimizing Antifungal Prescription) study, high use of nystatin in hospitalized children beyond the neonatal age was observed. In this report, we present the data on nystatin use in infants and children ≥ 3 months who participated in the PASOAP study. Nystatin was prescribed mainly for prophylaxis. Congenital heart disease, cystic fibrosis, and chronic renal disease were the most commonly reported conditions in children receiving prophylactic nystatin. There is sparse evidence supporting the use of nystatin prophylaxis beyond neonates; trials in specific pediatric patient groups are required.


  • Serial (1–3)-beta-D-Glucan (BDG) monitoring shows high variability among premature neonates

    by Laura Ferreras-Antolin, Nasreen Aziz, Adilia Warris

    This study aimed to characterize the baseline values and dynamics of serum (1,3)-Beta-D-Glucan (BDG) in neonates at high risk of neonatal invasive candidiasis (NIC); as well as to determine the effect of various clinical variables on these levels. Single center prospective cohort study was performed including 20 high-risk neonates (gestational age < 29 weeks and/or birth weight ≤ 1000 gr). Samples for BDG (Fungitell® assay) were obtained twice weekly during 6 weeks. Nineteen neonates were enrolled with a median gestational age of 25 weeks (IQR 24–27), median birth weight of 730 gr (IQR 650–810). None of the neonates was diagnosed with NIC. 190 serum samples were included. The median BDG value was 59 pg/ml (IQR 30–148), mean was 119 pg/ml (SD ± 154). A total of 42.1% (80/190) samples showed values ≥80 pg/ml, with all the neonates presenting at least one test above this cut-off. Neonatal age did not show an association with BDG levels. Exposure to steroids and the use of a heel prick as sampling method were associated with statistically significant higher BDG levels. The BDG levels showed high variability and in a significant proportion of samples values were above the threshold for positivity (e.g., ≥80 pg/ml) in the absence of NIC. The exposure to postnatal steroids and the heel prick as the method of blood sampling were associated with higher BDG levels. Lay Summary: Neonatal invasive candidiasis (NIC) presents high morbi-mortality. The diagnosis of NIC is often challenging. Blood cultures have limitations and better diagnostic tools are needed. Beta-D-glucan is a diagnostic marker which could be potentially used, although still more clinical data are required.


  • Open Access

    1288 Assessing the feasibility and compliance with a local screening pathway for infectious diseases in unaccompanied asylum seeking children (UASC)

    by Jaspreet Kaur Sokhi, Laura Ferreras Antolin

    Background NICE guidelines on looked after children (LAC) state that all UASC should have the necessary screening tests depending on their country of origin and these should be acted on appropriately to prevent transmission of infectious diseases. For this purpose, a local protocol was designed in 2018 to summarise the investigations that should be done at an initial UASC assessment and when a referral is required to Paediatric Infectious Diseases for further management. Objectives 1. To determine if UASC are investigated for infectious diseases as per the NICE recommendations following the introduction of a local screening pathway. 2. To determine if the results of the investigations are being acted on appropriately and in a timely manner 3. To identify areas of possible improvement in the care of the UASC Methods Retrospective data collection on UASC children (< 18 years of age) seen at our hospital over the last four years (January 2017 to August 2020). From January to December 2017 there wasn’t any local protocol in place. In January 2018, a local pathway was introduced. UASC were identified from the hospital UASC data base. Clinical notes were reviewed by the audit team and fully anonymised data was entered in a specifically created data collection tool. Descriptive analysis was performed. Both periods of time (prior and post implementation of the pathway) were compared. Results A total of 91 children were assessed (20/91 and 71/91 prior and after the introduction of the protocol). The majority of patients seen in both time periods were male (80/91) with a median age of 16 years, a minimum age of 6 years and a maximum age of 18.5 years. The most frequent countries of origin were Afghanistan (14/91) and Eritrea (17/91) although the number of UASC from Vietnam increased significantly in the second period (14/91). The proportion of patients seen who received part of the infectious diseases screening increased from 7% to 39% since the introduction of the local pathway. However even in those that the investigations were done, there was significant variability in which tests were ordered. For those patients who had investigations requested, 37.5% of them had their results available to the LAC team. The others’ results were not available to the LAC team and were still in the hands of the GP. The proportion of patients who received the complete infection screen was much lower at 29.5% (21/71) with only 9.5% (2/21)of those patients having all their results available to the LAC team. GPs were requested to carry out revaccination in most cases but there was no clear feedback and registration as to whether this was actually done in 89.3% of cases. Conclusions 1. The introduction of a local protocol was effective but still sub-optimal, highlighting the need for parallel actions such as access to results and collaboration between primary care services and the hospital. 2. Subsequent to this audit a new pathway agreed by the team was generated and a re-audit process will take place in 6 months’ time after introduction and training on the pathway.